| 1. | | Suspended | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer |
| 2. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Conditions: adult Hodgkin's lymphoma; adult T-cell leukemia and lymphoma; adult non-Hodgkin's lymphoma; adult solid tumor; Cutaneous T-Cell Lymphoma; ... |
| 3. | | Recruiting | 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
Conditions: refractory plasma cell neoplasm; stage III multiple myeloma; unspecified adult solid tumor, protocol specific |
| 4. | | Recruiting | 3-AP as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma (Cancer) of the Pancreas
Conditions: adenocarcinoma of the pancreas; recurrent pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; ... |
| 5. | | No longer recruiting | 4'-Iodo-4'-deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Condition: primary systemic amyloidosis |
| 6. | | No longer recruiting | BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma
Conditions: stage IVB adult soft tissue sarcoma; recurrent adult soft tissue sarcoma; stage IVA adult soft tissue sarcoma; stage III adult soft tissue sarcoma |
| 7. | | Recruiting | Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
Conditions: adult primary hepatocellular carcinoma; advanced adult primary liver cancer; localized unresectable adult primary liver cancer; ... |
| 8. | | Recruiting | CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
Conditions: recurrent adult soft tissue sarcoma; stage I adult soft tissue sarcoma; stage II adult soft tissue sarcoma; stage III adult soft tissue sarcoma; ... |
| 9. | | No longer recruiting | Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma
Condition: Multiple Myeloma |
| 10. | | Recruiting | Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors
Conditions: childhood central nervous system germ cell tumor; extragonadal germ cell tumor; adult central nervous system germ cell tumor; ... |
| 11. | | Recruiting | Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: recurrent ovarian epithelial cancer; stage IV ovarian epithelial cancer; peritoneal cavity cancer |
| 12. | | Recruiting | Combination Chemotherapy in Treating Patients With Advanced Cancer
Condition: unspecified adult solid tumor, protocol specific |
| 13. | | Recruiting | Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Condition: unspecified adult solid tumor, protocol specific |
| 14. | | No longer recruiting | Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia
Conditions: Leukemia, Myeloid, Aggressive-Phase; Neutropenia; recurrent adult acute lymphoblastic leukemia; relapsing chronic myelogenous leukemia; ... |
| 15. | | Completed | Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors
Condition: unspecified adult solid tumor, protocol specific |
| 16. | | Completed | Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
Condition: unspecified adult solid tumor, protocol specific |
| 17. | | No longer recruiting | Dolastatin 10 in Treating Patients With Advanced Kidney Cancer
Conditions: Stage IV Renal Cell Cancer; recurrent renal cell cancer |
| 18. | | Suspended | Erlotinib and Irinotecan in Treating Patients With Advanced Solid Tumors
Condition: unspecified adult solid tumor, protocol specific |
| 19. | | Recruiting | Erlotinib and Tipifarnib in Treating Patients With Advanced Solid Tumors
Condition: unspecified adult solid tumor, protocol specific |
| 20. | | Suspended | Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
Conditions: adult primary liver cancer; extrahepatic bile duct cancer; Gallbladder Cancer |
| 21. | | No longer recruiting | Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas
Conditions: adult malignant ependymoma; adult well-differentiated ependymoma; recurrent adult brain tumor |
| 22. | | No longer recruiting | Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 23. | | No longer recruiting | Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
Conditions: stage IV breast cancer; recurrent breast cancer; stage IV prostate cancer; recurrent prostate cancer; Stage IV Melanoma; Recurrent Melanoma; ... |
| 24. | | Recruiting | FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma
Conditions: recurrent adult diffuse large cell lymphoma; recurrent mantle cell lymphoma |
| 25. | | Suspended | Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma; gastrointestinal carcinoid tumor; Insulinoma; Islet Cell Carcinoma; metastatic gastrointestinal carcinoid tumor; ... |
| 26. | | No longer recruiting | High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse
Conditions: stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
| 27. | | Completed | Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma |
| 28. | | Completed | Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Condition: primary systemic amyloidosis |
| 29. | | Recruiting | Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
Condition: unspecified adult solid tumor, protocol specific |
| 30. | | Recruiting | MDX-010 in Treating Patients With Recurrent or Refractory B-Cell Follicular Lymphoma
Conditions: recurrent grade 1 follicular lymphoma; recurrent grade 2 follicular lymphoma |
| 31. | | No longer recruiting | Melanoma Vaccine With or Without Sargramostim in Treating Patients With Stage IV Malignant Melanoma
Conditions: Stage IV Melanoma; Recurrent Melanoma |
| 32. | | Recruiting | Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer
Conditions: adenocarcinoma of the prostate; stage II prostate cancer; stage III prostate cancer |
| 33. | | Recruiting | Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
Conditions: inflammatory breast cancer; Male Breast Cancer; stage IIIA breast cancer; stage IIIB breast cancer; unspecified adult solid tumor, protocol specific |
| 34. | | Suspended | Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia |
| 35. | | No longer recruiting | Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma
Conditions: recurrent adult soft tissue sarcoma; stage III adult soft tissue sarcoma; stage IVA adult soft tissue sarcoma; stage IVB adult soft tissue sarcoma |
| 36. | | No longer recruiting | Phase II Randomized Controlled Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy
Condition: Graves' Disease |
| 37. | | No longer recruiting | Phase III Randomized Study of Vapreotide in Patients Undergoing Elective Pancreatic Resection
Conditions: perioperative/postoperative complications; stage I pancreatic cancer |
| 38. | | No longer recruiting | PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Condition: unspecified adult solid tumor, protocol specific |
| 39. | | No longer recruiting | PS-341 in Treating Patients With Advanced Cancer
Conditions: Leukemia; Multiple Myeloma; Lymphoma |
| 40. | | No longer recruiting | PS-341 in Treating Patients With Metastatic Malignant Melanoma
Conditions: Stage IV Melanoma; Recurrent Melanoma |
| 41. | | No longer recruiting | R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
Conditions: stage IV non-small cell lung cancer; recurrent non-small cell lung cancer |
| 42. | | Recruiting | Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Conditions: grade 1 follicular lymphoma; grade 2 follicular lymphoma; grade 3 follicular lymphoma; indolent, adult non-Hodgkin's lymphoma; marginal zone lymphoma; ... |
| 43. | | Not yet recruiting | Rituximab and Fludarabine Followed by Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Chronic Lymphocytic Leukemia or Non-Hodgkin's Lymphoma
Conditions: adult non-Hodgkin's lymphoma; Chronic Lymphocytic Leukemia; indolent or aggressive adult non-Hodgkin's lymphoma |
| 44. | | Recruiting | Screening Tests in Detecting Colorectal Cancer
Conditions: Colon Cancer; Rectal Cancer |
| 45. | | No longer recruiting | Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas
Conditions: stage I pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer; adenocarcinoma of the pancreas |
| 46. | | No longer recruiting | Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia
Conditions: chronic idiopathic myelofibrosis; Polycythemia Vera; Essential Thrombocythemia |
| 47. | | Recruiting | Tipifarnib in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Conditions: adult non-Hodgkin's lymphoma; anaplastic large cell lymphoma; Chronic Lymphocytic Leukemia; indolent or aggressive adult non-Hodgkin's lymphoma; ... |
| 48. | | No longer recruiting | Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Conditions: stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer |
| 49. | | Recruiting | Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer
Conditions: adenocarcinoma of the prostate; stage IV prostate cancer; recurrent prostate cancer |
